indobufen
Small moleculeexperimental
Indobufen is a platelet aggregation inhibitor. It acts as a reversible cyclooxygenase inhibitor. — Wikipedia
Clinical trial activity
9 trials · 12 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
1
Phase 4
5
Earliest trial started Dec 1, 2000 (NCT00244426)
Timeline
Indications
Approved for
Mechanism of action
- CyclooxygenaseINHIBITOR
Cyclooxygenase inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
CCC(C(=O)O)c1ccc(N2Cc3ccccc3C2=O)cc1- Mol. weight
- 295.34 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Racemic Mixture
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaIndobufen ↗
- ChEMBLCHEMBL1765292 ↗
Also known as
- 2-(4-(1-oxo-2-isoindolinyl)phenyl)butyric acid
- 4-(1,3-dihydro-1-oxo-2h-isoindol-2-yl) alpha- ethylbenzeneacetic acid
- ibustrin
- ibustrin
- indobufen
- indobufen
- indobufen
- indobufen
- indobufen
- indobufen
- indobufen
- indobufen
- indobufen, (+-)-isomer
- k 3920
- k 3920
- k-3920
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07089862 | N/A | Aug 31, 2025 | Capital Medical University, China Medical University, Fujian Medical University, Jiao Tong University, The Central Hospital of Lishui City |
| NCT06451198 | Phase 4 | Jul 1, 2024 | Fudan University |
| NCT05105750 | Phase 4 | Oct 30, 2021 | Nanjing Medical University |
| NCT04308551 | N/A | Mar 16, 2020 | Chinese Academy of Medical Sciences, Henan Institute of Cardiovascular Epidemiology |
| NCT04129008 | Phase 4 | Oct 17, 2019 | Capital Medical University |
| NCT03871517 | Phase 4 | May 1, 2019 | Government of China |
| NCT03230851 | Phase 4 | Aug 20, 2017 | Nanjing Medical University |
| NCT01232023 | Phase 1 | Jan 1, 2010 | University of Ulsan |
| NCT00244426 | Phase 3 | Dec 1, 2000 | Pfizer |
Showing 9 of 9 trials
Page 1 / 1
Organizations
Research & Development (12)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Capital Medical University | Academic/Hospital | 2 | 2 | 2 | 2019 |
| Nanjing Medical University | Academic/Hospital | 2 | 2 | 1 | 2017 |
| China Medical University | Academic/Hospital | 1 | 0 | 1 | 2025 |
| Chinese Academy of Medical Sciences | Academic/Hospital | 1 | 0 | 1 | 2020 |
| Fudan University | Academic/Hospital | 1 | 1 | 1 | 2024 |
| Fujian Medical University | Academic/Hospital | 1 | 0 | 1 | 2025 |
| Government of China | Government | 1 | 1 | 1 | 2019 |
| Henan Institute of Cardiovascular Epidemiology | Academic/Hospital | 1 | 1 | 1 | 2020 |
| Jiao Tong University | Academic/Hospital | 1 | 0 | 1 | 2025 |
| Pfizer | For profit | 1 | 1 | 1 | 2000 |
| The Central Hospital of Lishui City | Academic/Hospital | 1 | 0 | 1 | 2025 |
| University of Ulsan | Academic/Hospital | 1 | 1 | 1 | 2010 |
12 organizations
Page 1 / 1